Omnicell (OMCL) Competitors

$43.33 -0.43 (-0.98%)

Closing price 04:00 PM Eastern

Extended Trading

$43.12 -0.21 (-0.48%)

As of 05:41 PM Eastern

OMCL vs. MASI, AMN, WST, HSTM, and MDRX

Should you be buying Omnicell stock or one of its competitors? The main competitors of Omnicell include Masimo (MASI), AMN Healthcare Services (AMN), West Pharmaceutical Services (WST), HealthStream (HSTM), and Veradigm (MDRX).

How does Omnicell compare to Masimo?

Masimo (NASDAQ:MASI) and Omnicell (NASDAQ:OMCL) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

: Masimo has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500. Comparatively, Omnicell has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500.
: Omnicell has a net margin of 1.67% compared to Masimo's net margin of -9.92%. Masimo's return on equity of 32.02% beat Omnicell's return on equity.
Company Net Margins Return on Equity Return on Assets
Masimo -9.92% 32.02% 13.73%
Omnicell 1.67% 4.00% 2.46%
: 86.0% of Masimo shares are owned by institutional investors. Comparatively, 97.7% of Omnicell shares are owned by institutional investors. 9.7% of Masimo shares are owned by insiders. Comparatively, 2.9% of Omnicell shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
: Omnicell has lower revenue, but higher earnings than Masimo. Masimo is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Masimo $1.53B 6.10 -$151.50M -$10.54 N/A
Omnicell $1.23B 1.61 $2.05M $0.44 98.48
: In the previous week, Masimo had 5 more articles in the media than Omnicell. MarketBeat recorded 9 mentions for Masimo and 4 mentions for Omnicell. Masimo's average media sentiment score of 0.87 beat Omnicell's score of 0.46 indicating that Masimo is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Masimo
4 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Omnicell
0 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Masimo presently has a consensus price target of $180.40, indicating a potential upside of 1.06%. Omnicell has a consensus price target of $59.86, indicating a potential upside of 38.14%. Given Omnicell's stronger consensus rating and higher probable upside, analysts plainly believe Omnicell is more favorable than Masimo.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Masimo
0 Sell rating(s)
9 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
2.00
Omnicell
1 Sell rating(s)

0 Hold rating(s)

7 Buy rating(s)

1 Strong Buy rating(s)
2.89

Company	Net Margins	Return on Equity	Return on Assets
Masimo	-9.92%	32.02%	13.73%
Omnicell	1.67%	4.00%	2.46%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Masimo	$1.53B	6.10	-$151.50M	-$10.54	N/A
Omnicell	$1.23B	1.61	$2.05M	$0.44	98.48

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Masimo	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Omnicell	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Masimo	0 Sell rating(s)	9 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Omnicell	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Summary

Omnicell beats Masimo on 9 of the 17 factors compared between the two stocks.

How does Omnicell compare to AMN Healthcare Services?

AMN Healthcare Services (NYSE:AMN) and Omnicell (NASDAQ:OMCL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings.

: AMN Healthcare Services has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500. Comparatively, Omnicell has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500.
: Omnicell has lower revenue, but higher earnings than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AMN Healthcare Services $2.73B 0.32 -$95.70M -$2.49 N/A
Omnicell $1.23B 1.61 $2.05M $0.44 98.48
: 99.2% of AMN Healthcare Services shares are held by institutional investors. Comparatively, 97.7% of Omnicell shares are held by institutional investors. 1.1% of AMN Healthcare Services shares are held by company insiders. Comparatively, 2.9% of Omnicell shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
: In the previous week, AMN Healthcare Services had 3 more articles in the media than Omnicell. MarketBeat recorded 7 mentions for AMN Healthcare Services and 4 mentions for Omnicell. Omnicell's average media sentiment score of 0.46 beat AMN Healthcare Services' score of 0.29 indicating that Omnicell is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
AMN Healthcare Services
0 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Omnicell
0 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: AMN Healthcare Services presently has a consensus target price of $22.64, suggesting a potential upside of 0.68%. Omnicell has a consensus target price of $59.86, suggesting a potential upside of 38.14%. Given Omnicell's stronger consensus rating and higher possible upside, analysts clearly believe Omnicell is more favorable than AMN Healthcare Services.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AMN Healthcare Services
2 Sell rating(s)
2 Hold rating(s)

4 Buy rating(s)

1 Strong Buy rating(s)
2.44
Omnicell
1 Sell rating(s)

0 Hold rating(s)

7 Buy rating(s)

1 Strong Buy rating(s)
2.89
: Omnicell has a net margin of 1.67% compared to AMN Healthcare Services' net margin of -3.51%. AMN Healthcare Services' return on equity of 8.05% beat Omnicell's return on equity.
Company Net Margins Return on Equity Return on Assets
AMN Healthcare Services -3.51% 8.05% 2.38%
Omnicell 1.67% 4.00% 2.46%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AMN Healthcare Services	$2.73B	0.32	-$95.70M	-$2.49	N/A
Omnicell	$1.23B	1.61	$2.05M	$0.44	98.48

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AMN Healthcare Services	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Omnicell	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AMN Healthcare Services	2 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.44
Omnicell	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Company	Net Margins	Return on Equity	Return on Assets
AMN Healthcare Services	-3.51%	8.05%	2.38%
Omnicell	1.67%	4.00%	2.46%

Summary

Omnicell beats AMN Healthcare Services on 12 of the 16 factors compared between the two stocks.

How does Omnicell compare to West Pharmaceutical Services?

West Pharmaceutical Services (NYSE:WST) and Omnicell (NASDAQ:OMCL) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

: West Pharmaceutical Services has higher revenue and earnings than Omnicell. West Pharmaceutical Services is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
West Pharmaceutical Services $3.07B 7.41 $493.70M $7.48 43.11
Omnicell $1.23B 1.61 $2.05M $0.44 98.48
: In the previous week, West Pharmaceutical Services had 3 more articles in the media than Omnicell. MarketBeat recorded 7 mentions for West Pharmaceutical Services and 4 mentions for Omnicell. West Pharmaceutical Services' average media sentiment score of 1.29 beat Omnicell's score of 0.46 indicating that West Pharmaceutical Services is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
West Pharmaceutical Services
5 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Omnicell
0 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: West Pharmaceutical Services currently has a consensus target price of $322.89, indicating a potential upside of 0.14%. Omnicell has a consensus target price of $59.86, indicating a potential upside of 38.14%. Given Omnicell's stronger consensus rating and higher probable upside, analysts plainly believe Omnicell is more favorable than West Pharmaceutical Services.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
West Pharmaceutical Services
0 Sell rating(s)
4 Hold rating(s)

7 Buy rating(s)

1 Strong Buy rating(s)
2.75
Omnicell
1 Sell rating(s)

0 Hold rating(s)

7 Buy rating(s)

1 Strong Buy rating(s)
2.89
: West Pharmaceutical Services has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500. Comparatively, Omnicell has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500.
: West Pharmaceutical Services has a net margin of 16.85% compared to Omnicell's net margin of 1.67%. West Pharmaceutical Services' return on equity of 19.03% beat Omnicell's return on equity.
Company Net Margins Return on Equity Return on Assets
West Pharmaceutical Services 16.85% 19.03% 14.06%
Omnicell 1.67% 4.00% 2.46%
: 93.9% of West Pharmaceutical Services shares are owned by institutional investors. Comparatively, 97.7% of Omnicell shares are owned by institutional investors. 0.6% of West Pharmaceutical Services shares are owned by insiders. Comparatively, 2.9% of Omnicell shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
West Pharmaceutical Services	$3.07B	7.41	$493.70M	$7.48	43.11
Omnicell	$1.23B	1.61	$2.05M	$0.44	98.48

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
West Pharmaceutical Services	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Omnicell	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
West Pharmaceutical Services	0 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.75
Omnicell	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Company	Net Margins	Return on Equity	Return on Assets
West Pharmaceutical Services	16.85%	19.03%	14.06%
Omnicell	1.67%	4.00%	2.46%

Summary

West Pharmaceutical Services beats Omnicell on 10 of the 15 factors compared between the two stocks.

How does Omnicell compare to HealthStream?

HealthStream (NASDAQ:HSTM) and Omnicell (NASDAQ:OMCL) are both small-cap health care technology companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk and institutional ownership.

: HealthStream has higher earnings, but lower revenue than Omnicell. HealthStream is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
HealthStream $311.78M 2.22 $18.34M $0.67 35.13
Omnicell $1.23B 1.61 $2.05M $0.44 98.48
: In the previous week, HealthStream had 9 more articles in the media than Omnicell. MarketBeat recorded 13 mentions for HealthStream and 4 mentions for Omnicell. HealthStream's average media sentiment score of 0.62 beat Omnicell's score of 0.46 indicating that HealthStream is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
HealthStream
1 Very Positive mention(s)
4 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Omnicell
0 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: 69.6% of HealthStream shares are owned by institutional investors. Comparatively, 97.7% of Omnicell shares are owned by institutional investors. 20.4% of HealthStream shares are owned by company insiders. Comparatively, 2.9% of Omnicell shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
: HealthStream has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500. Comparatively, Omnicell has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500.
: HealthStream has a net margin of 6.39% compared to Omnicell's net margin of 1.67%. HealthStream's return on equity of 6.47% beat Omnicell's return on equity.
Company Net Margins Return on Equity Return on Assets
HealthStream 6.39% 6.47% 4.44%
Omnicell 1.67% 4.00% 2.46%
: HealthStream presently has a consensus target price of $24.00, indicating a potential upside of 1.95%. Omnicell has a consensus target price of $59.86, indicating a potential upside of 38.14%. Given Omnicell's stronger consensus rating and higher possible upside, analysts clearly believe Omnicell is more favorable than HealthStream.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
HealthStream
1 Sell rating(s)
2 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
1.67
Omnicell
1 Sell rating(s)

0 Hold rating(s)

7 Buy rating(s)

1 Strong Buy rating(s)
2.89

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HealthStream	$311.78M	2.22	$18.34M	$0.67	35.13
Omnicell	$1.23B	1.61	$2.05M	$0.44	98.48

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HealthStream	1 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Omnicell	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
HealthStream	6.39%	6.47%	4.44%
Omnicell	1.67%	4.00%	2.46%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HealthStream	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Omnicell	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Summary

HealthStream beats Omnicell on 9 of the 17 factors compared between the two stocks.

How does Omnicell compare to Veradigm?

Veradigm (NASDAQ:MDRX) and Omnicell (NASDAQ:OMCL) are both small-cap health care technology companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, media sentiment, dividends, earnings, valuation and risk.

: Omnicell has lower revenue, but higher earnings than Veradigm.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Veradigm $1.53B 0.37 N/A N/A N/A
Omnicell $1.23B 1.61 $2.05M $0.44 98.48
: Omnicell has a consensus price target of $59.86, indicating a potential upside of 38.14%. Given Omnicell's stronger consensus rating and higher probable upside, analysts clearly believe Omnicell is more favorable than Veradigm.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Veradigm
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Omnicell
1 Sell rating(s)

0 Hold rating(s)

7 Buy rating(s)

1 Strong Buy rating(s)
2.89
: Omnicell has a net margin of 1.67% compared to Veradigm's net margin of 0.00%. Omnicell's return on equity of 4.00% beat Veradigm's return on equity.
Company Net Margins Return on Equity Return on Assets
Veradigm N/A N/A N/A
Omnicell 1.67% 4.00% 2.46%
: 97.7% of Omnicell shares are owned by institutional investors. 2.3% of Veradigm shares are owned by company insiders. Comparatively, 2.9% of Omnicell shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
: In the previous week, Omnicell had 2 more articles in the media than Veradigm. MarketBeat recorded 4 mentions for Omnicell and 2 mentions for Veradigm. Omnicell's average media sentiment score of 0.46 beat Veradigm's score of 0.00 indicating that Omnicell is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Veradigm
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Omnicell
0 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Veradigm has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500. Comparatively, Omnicell has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradigm	$1.53B	0.37	N/A	N/A	N/A
Omnicell	$1.23B	1.61	$2.05M	$0.44	98.48

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradigm	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Omnicell	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Company	Net Margins	Return on Equity	Return on Assets
Veradigm	N/A	N/A	N/A
Omnicell	1.67%	4.00%	2.46%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veradigm	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Omnicell	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Omnicell beats Veradigm on 14 of the 15 factors compared between the two stocks.

Get Omnicell News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OMCL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OMCL vs. The Competition

Export

Metric	Omnicell	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.97B	$1.49B	$6.22B	$12.11B
Dividend Yield	N/A	N/A	2.74%	5.26%
P/E Ratio	98.48	61.80	28.56	27.26
Price / Sales	1.61	21.65	535.48	83.61
Price / Cash	15.75	24.69	43.35	54.56
Price / Book	1.57	4.82	9.88	6.90
Net Income	$2.05M	-$54.60M	$3.54B	$333.00M
7 Day Performance	4.61%	1.83%	1.57%	1.87%
1 Month Performance	25.59%	10.52%	6.13%	8.64%
1 Year Performance	75.92%	7.37%	43.01%	43.19%

Omnicell Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OMCL Omnicell	2.8922 of 5 stars	$43.33 -1.0%	$59.86 +38.1%	+70.5%	$1.97B	$1.23B	98.48	3,580
MASI Masimo	1.4068 of 5 stars	$178.21 -0.2%	$181.17 +1.7%	+10.5%	$9.59B	$1.53B	N/A	2,200	Analyst Upgrade
AMN AMN Healthcare Services	1.7178 of 5 stars	$20.76 -1.7%	$22.64 +9.0%	+7.2%	$816.10M	$2.73B	N/A	2,664	Earnings Report
WST West Pharmaceutical Services	3.7722 of 5 stars	$300.27 -0.1%	$322.89 +7.5%	+52.7%	$21.24B	$3.07B	40.14	10,800	Positive News
HSTM HealthStream	2.4696 of 5 stars	$21.25 +2.6%	$25.00 +17.6%	-13.7%	$609.62M	$304.06M	34.84	1,160	Earnings Report Dividend Announcement Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OMCL) was last updated on 5/7/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Omnicell (OMCL) Competitors

OMCL vs. MASI, AMN, WST, HSTM, and MDRX

How does Omnicell compare to Masimo?

Summary

How does Omnicell compare to AMN Healthcare Services?

Summary

How does Omnicell compare to West Pharmaceutical Services?

Summary

How does Omnicell compare to HealthStream?

Summary

How does Omnicell compare to Veradigm?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OMCL vs. The Competition

Omnicell Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Omnicell (OMCL) Competitors

OMCL vs. MASI, AMN, WST, HSTM, and MDRX

How does Omnicell compare to Masimo?

Summary

How does Omnicell compare to AMN Healthcare Services?

Summary

How does Omnicell compare to West Pharmaceutical Services?

Summary

How does Omnicell compare to HealthStream?

Summary

How does Omnicell compare to Veradigm?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OMCL vs. The Competition

Omnicell Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools